There are 36 states in the US that have made medical marijuana legal with four more states expected to vote on legalization in the next 12 months. Cannabis as medicine isn’t new but now its on a hockey stick trajectory, with the global medical marijuana market expected to grow at ~22.9% compound annual growth rate until it reaches USD$44.4 billion by 2025. Canntab Therapeutics (PILL.C) is leading the charge in this nascent market with the development of strong IP in terms of therapeutic cannabis formulations and drug delivery methods. Until recently, THC-based therapeutics were smoked, eaten or drank. None of which provided consistent dosing or bioavailability. Doctors were desperate for a lab-quality answer, so Canntab came up with it by extracting the medicinal compounds found in cannabis and pressing them into pills, ensuring accurate dosage and distribution throughout the body. Canntab utilizes a four-pronged revenue model based on licensing, hard pill product sales, manufacturing profit and online store sales starting Q2 2021. The company’s IP portfolio contains one US patent and its first Canadian, even wider than the US, both of which remain active until 2038, and also eight more pending for proprietary processes and hard pill formulations. Focusing on the Opioid crisis which killed one Canadian every two hours in 2018, Canntab will conduct a clinical study in 2021 with leading orthopedic surgeon, Dr. Donald Garbuz at UBC to show the potential for reduction in the use of opiates in post-operative pain care using Canntab’s modified multi-release formulation with high CBD and low THC. The company intends to use these efforts to obtain a Cannabis Drug Establishment License, with clinical support and then Drug Identification Numbers for Canntab’s product pipeline. With expert management, a tight 44 million shares, two patents for immediate release cannabidiol formulation tablets and three pill products including an oral dissolving pill, an instant release pill and an extended-release pill due to be marketed by the end of 2021, Canntab is poised to be an industry leader with significant market cap growth for its investors. Full disclosure: Canntab is an Equity.Guru marketing client
